Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment

Thrombosis and Haemostasis

Volumn 101, Issue 5, 2009, Pages 938-942

  Poli, Daniela ^a,b   Antonucci, Emilia ^a,b   Grifoni, Elisa ^a,b   Abbate, Rosanna ^a,b   Gensini, Gian Franco ^a,b,c   Prisco, Domenico ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Atrial fibrillation; Female gender; Quality of anticoagulation; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENDER; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE HEMATOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; RISK FACTOR; STROKE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; HEALTHCARE DISPARITIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN; WOMEN'S HEALTH;

EID: 66149175573     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0635     Document Type: Article

References (35)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292. (Pubitemid 39407328)
3. Lip GY, Watson T, Shantsila E. Anticoagulation for stroke prevention in atrial fibrillation: is gender important? Eur Heart J 2006; 27: 1893-1894.
4. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-1229.
5. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056. (Pubitemid 37430445)
6. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
7. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol 1989; 63: 366-667. (Pubitemid 19049253)
8. Petersen P, Kastrup J, Helweg-Larsen S, et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Intern Med 1990; 150: 819-821.
9. Aronow WS, Ahn C, Kronzon I, et al. Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. Am J Cardiol 1998; 82: 119-121. (Pubitemid 28322044)
10. Nakagami H, Yamamoto K, Ikeda U, et al. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J 1998; 136: 528-532. (Pubitemid 28413554)
11. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. J Am Med Assoc 1998; 279: 1273-1277.
12. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687-1691. (Pubitemid 41368143)
13. Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. Q J Med 2007; 100: 599-607.
14. Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin: predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009; 101: 367-372.
15. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S-206S. (Pubitemid 32154200)
16. Iliceto S. A guide to Oral Anticoagulant Therapy: Recommendation of Italian Federation of Anticoagulation Clinics. Haematologica 2003; 88 (Suppl 2): 1.
17. Poller L, Keown M, Ibrahim S, et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6: 935-943.
18. Rosendaal FR, Cannegieter SC, van der Meer FJM, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239. (Pubitemid 23069000)
19. Bonita R, Beaglehole R. Modification of Rankin scale: recovery of motor function after stroke. Stroke 1988; 19: 1497-1500.
20. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (IS-COAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428. (Pubitemid 26267872)
21. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870. (Pubitemid 32537350)
22. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Lippincott-Raven, 1998.
23. Rothman KJ. Epidemiology. Chap. 3, Ed. Oxford University 2002; p. 46-49.
24. Poli D, Antonucci E, Marcucci R, et al. The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. Int J Cardiol 2009; 132: 109-113.
25. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001; 85: 418-422.
26. Gomberg-Maitland M, Wenger NK, Feyzi J, et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006; 27: 1947-1953. (Pubitemid 44297369)
27. Poli D, Antonucci E, Cecchi E, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 2005; 36: 2159-2163. (Pubitemid 41429238)
28. Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82: 580-583. (Pubitemid 28397656)
29. Nichol MB, Knight TK, Dow T, et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008; 4: 62-70.
30. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-1647. (Pubitemid 28371187)
31. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752. (Pubitemid 39524912)
32. Schulman S, Beyth RJ, Kearon C, et al.; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest 2008; 133: 257S-298S.
33. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245. (Pubitemid 46256540)
34. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. (Pubitemid 37087616)
35. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117: 493-499. (Pubitemid 43326133)